PIRS Pieris Pharmaceuticals, Inc. Company Cash Funds

Public company logo of pieris.com (PIRS)

Pieris Pharmaceuticals (PIRS) faces significant business risks due to a capital shortage and potential research failures. The cash balance shown on the GURU.Markets temporary chart confirms this trend, with the metric currently standing at 0.26. Anticalin protein patents and lobbying efforts serve as a defense, despite strict FDA oversight. However, the severance of ties with industry behemoths has triggered a prolonged liquidity crisis.

Pieris - PIRS Company Cash Balance (period 07/04/2022 - 11/21/2026)

Financial and market metric breakdowns for Pieris Pharmaceuticals, Inc. (PIRS)

- stock quotes and analyst forecast:
Comprehensive company analysis:PIRS Pieris Pharmaceuticals
Brand item of pieris.com

Global scaling of the Anticalin protein platform requires colossal expenditures on clinical trials and B2B partnerships. This metric measures the volume of liquid assets, determining the ability of Pieris Pharmaceuticals (PIRS) to finance expansion without external borrowing. By analyzing the cash flow chart on GURU.Markets, an investor assesses the burn rate. Liquidity dynamics directly confirm the issuer's solvency. A stable cash balance guarantees the fundamental stability of the asset.

Direct competitors

Company Cash Funds Haleon (HLN)|Company Cash Volume Kenvue Inc. (KVUE)|Company Cash Volume VRNA (veronapharma.com)|Company Cash Balance MENS|LGND: Company Cash on Hand|Company Cash Balance AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Company Cash on Hand|Alvotech - Company Cash Balance|Company Cash on Hand LQDA|Galapagos Genomics (GLPG) - Company Liquid Assets|Company Cash Volume ANIP|Company Cash on Hand Afrezza MNKD|Company Cash Funds Amphastar AMPH|Company Liquid Assets Pacira BioSciences (PCRX)|ARS Corp - Company Cash Volume|TBPH: Company Cash Funds|AQST: Company Cash Volume|SCPH - Company Liquid Assets|TECX (Tectonic) - Company Cash Volume|Company Cash Reserve Tonix Pharmaceuticals Holding Corp. TNXP|Company Cash Funds SXT Pharmaceuticals (SXTC)|Company Cash Volume Eupraxia Pharmaceuticals Inc. (EPRX)|Company Cash Funds BioHarvest Sciences BHST|EXOZ (Invizyne) - Company Total Cash Volume|ORMP: Company Cash on Hand|ENTX (Entera Bio Ltd) - Company Cash and Cash Equivalents|HYFT: Company Cash Volume|Company Cash on Hand ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Company Cash Volume|Company Cash Funds QNTM|Company Cash Volume FGEN|Company Cash on Hand Telomir Pharmaceuticals TELO|Company Cash Volume RANI (ranitherapeutics.com)|SNYR (Synergy CHC Corporation) - Company Total Cash Volume|RLYB - Company Cash Funds|LEXX (Lexaria Bioscience Corp.) - Company Cash and Cash Equivalents|pulmatrix.com (PULM) - Company Cash Funds|PTHL (Pheton) - Company Cash Funds|Company Cash Funds Aptorum|Company Cash Reserve Lyra Therapeutics Inc. LYRA|Company Cash Volume IBO|TNFA (TNF Pharmaceuticals, Inc.) - Company Cash Balance|Company Cash Funds cbdMD, Inc. YCBD|Company Cash Balance PRFX|Altamira Therapeutics Ltd. - Company Cash Volume|Company Cash Reserve Lipella Pharmaceuticals Inc|OPTN: Company Cash Volume|Procaps Group S.A. (PROC) - Company Cash Volume|PTPI (Petros Pharma) - Company Cash Volume|QLI: Company Cash Balance|Company Cash Volume SLRN|TFFP (TFF Pharmaceuticals Inc.) - Company Cash Balance